Toxoplasmosis in non-cardiac solid organ transplant recipients: A case series and review of literature

Transpl Infect Dis. 2020 Feb;22(1):e13218. doi: 10.1111/tid.13218. Epub 2019 Dec 12.

Abstract

The risk of toxoplasmosis in high-risk cardiac transplant recipients is well recognized prompting universal donor and candidate screening with administration of targeted post-transplant chemoprophylaxis in high-risk (D+/R-) cardiac transplant patients. In contrast, until recently, there have been neither well-defined recommendations nor consensus regarding toxoplasmosis preventive strategies among non-cardiac solid organ transplant recipients. We report 3 cases of post-transplant toxoplasmosis in non-cardiac transplant recipients (one lung and two liver); all 3 infections presumed to be donor-derived. Not surprisingly, pre-transplant Toxoplasma serology was negative in all the patients. None of the patients were on trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis at the time of diagnosis of toxoplasmosis. The median time from transplant to onset of infection was 90 days (range: 30-120 days). Clinical presentations included cerebral (n = 1) and disseminated infections (n = 2). Two of the 3 patients, both with disseminated infection died (mortality ~ 67%).

Keywords: solid organ transplant recipients; toxoplasmosis.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Chemoprevention
  • Fatal Outcome
  • Humans
  • Liver Transplantation / adverse effects*
  • Lung Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Tissue Donors*
  • Toxoplasmosis / diagnosis
  • Toxoplasmosis / drug therapy
  • Toxoplasmosis / etiology*
  • Transplant Recipients / statistics & numerical data*
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Young Adult

Substances

  • Trimethoprim, Sulfamethoxazole Drug Combination